Free Trial
LON:OXB

Oxford Biomedica (OXB) Share Price, News & Analysis

Oxford Biomedica logo
GBX 405
+7.00 (+1.76%)
(As of 11/1/2024 ET)

About Oxford Biomedica Stock (LON:OXB)

Key Stats

Today's Range
397.50
405.50
50-Day Range
327
445
52-Week Range
164.29
450
Volume
150,001 shs
Average Volume
204,654 shs
Market Capitalization
£426.71 million
P/E Ratio
N/A
Dividend Yield
4.57%
Price Target
GBX 433.33
Consensus Rating
Hold

Company Overview

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

Oxford Biomedica Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
12th Percentile Overall Score

OXB MarketRank™: 

Oxford Biomedica scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Oxford Biomedica has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Oxford Biomedica has only been the subject of 1 research reports in the past 90 days.

  • Read more about Oxford Biomedica's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oxford Biomedica is -281.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oxford Biomedica is -281.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Oxford Biomedica has a P/B Ratio of 6.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for OXB.
  • Dividend Leadership

    Oxford Biomedica is a leading dividend payer. It pays a dividend yield of 4.57%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Oxford Biomedica does not have a long track record of dividend growth.

  • Read more about Oxford Biomedica's dividend.
  • Short Interest

    There is no current short interest data available for OXB.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Oxford Biomedica this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    2 people have added Oxford Biomedica to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Oxford Biomedica insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    21.17% of the stock of Oxford Biomedica is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    64.13% of the stock of Oxford Biomedica is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Oxford Biomedica's insider trading history.
Receive OXB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter.

OXB Stock News Headlines

Oxford Biomedica Announces Total Voting Rights Update
Oxford BioMedica Sees Shift in Voting Rights
Sell NVDA Now?
Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.
See More Headlines

OXB Stock Analysis - Frequently Asked Questions

Oxford Biomedica's stock was trading at GBX 220 at the beginning of the year. Since then, OXB stock has increased by 84.1% and is now trading at GBX 405.
View the best growth stocks for 2024 here
.

Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford Biomedica (OXBDF) and Barclays (BARC).

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
891
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 433.33
High Stock Price Target
GBX 740
Low Stock Price Target
GBX 180
Potential Upside/Downside
+7.0%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
£-142,020,000.00
Net Margins
-145.98%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£97.28 million
Cash Flow
GBX 134.71 per share
Book Value
GBX 63 per share

Miscellaneous

Free Float
N/A
Market Cap
£426.71 million
Optionable
Not Optionable
Beta
1.09
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (LON:OXB) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners